MAM
ANIK icon

Martingale Asset Management’s Anika Therapeutics ANIK Stock Holding History

Martingale Asset Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$224K Buy
+15,312
New +$227K 0.01% 801
2024
Q4 		– Sell
-12,525
Closed -$309K – 767
2024
Q3 		$309K Hold
12,525
– – 0.01% 707
2024
Q2 		$317K Buy
12,525
+1
+0% +$26 0.01% 685
2024
Q1 		$318K Hold
12,524
– – 0.01% 700
2023
Q4 		$284K Sell
12,524
-4
-0% -$83 0.01% 712
2023
Q3 		$233K Sell
12,528
-1,170
-9% -$24.3K ﹤0.01% 725
2023
Q2 		$356K Buy
13,698
+1,776
+15% +$47.5K 0.01% 672
2023
Q1 		$342K Buy
+11,922
New +$355K 0.01% 688
2014
Q3 		– Sell
-8,155
Closed -$378K – 848
2014
Q2 		$378K Sell
8,155
-8,352
-51% -$371K 0.01% 743
2014
Q1 		$679K Buy
16,507
+1
+0% +$37 0.02% 612
2013
Q4 		$630K Buy
16,506
+2,202
+15% +$67.9K 0.02% 699
2013
Q3 		$342K Buy
+14,304
New +$321K 0.01% 852

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

Martingale Asset Management's ANIK Position: Q2 2026 in Review

Martingale Asset Management opened a new position in Anika Therapeutics (ANIK) in Q2 2026: 15,312 shares worth $224K. The stake represents 0.01% of the portfolio and ranks #801 among its holdings. This is a return to the name: Martingale Asset Management previously reported a position in ANIK as recently as Q3 2024.

Martingale Asset Management first reported a position in ANIK in Q3 2013 and has held it in 12 quarters since. The position peaked at $679K in Q1 2014. 133 funds tracked by Wall St. Rank hold ANIK as of Q2 2026.

  • Martingale Asset Management held 15,312 shares of Anika Therapeutics worth $224K as of Q2 2026.
  • Anika Therapeutics was a new Martingale Asset Management position in Q2 2026.
  • Anika Therapeutics made up 0.01% of Martingale Asset Management's portfolio in Q2 2026, its #801 holding.
  • Martingale Asset Management first reported a position in Anika Therapeutics in Q3 2013 and has held it in 12 quarters since.
  • Martingale Asset Management's Anika Therapeutics position peaked at $679K in Q1 2014.
  • 133 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2026.

Based on Martingale Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.